Dr. Shaun Xiaoliu Zhang, chair of the Department of Biology and Biochemistry at the University of Houston’s College of Natural Sciences (NSM), has been appointed Associate Editor of Molecular Therapy Oncology.
The appointment marks a significant professional milestone, as Dr. Zhang joins the editorial board of this prestigious international publication. Molecular Therapy Oncology is an official journal of the American Society of Gene and Cell Therapy (ASGCT), a global organization representing more than 6,000 members across 60 countries. For Dr. Zhang, the role is both a testament to his expertise and an opportunity to contribute to the advancement of cancer research.
“I feel proud to represent NSM and the University of Houston,” said Zhang. “It is an honor to take on this role because the journal serves the scientific community so well and is highly respected in the field of molecular therapy.”
A Leader in Cancer Innovation
Dr. Zhang’s appointment to the journal’s editorial leadership follows his extensive research efforts focused on developing treatments for solid tumors. His work centers on oncolytic virotherapy, a cutting-edge approach that re-engineers benign viruses, such as the herpes simplex virus (HSV), to selectively target and kill malignant cells while leaving healthy tissue unharmed.
His lab’s unique platform goes beyond directly attacking tumors. It acts as a “primer” for the body’s immune system. By arming viruses with novel molecules, Dr. Zhang aims to overcome the limitations of current immunotherapies and expand treatment options for the majority of cancer patients who do not respond to existing therapies.
Global Impact from Houston
As Associate Editor, Dr. Zhang will help shape the direction of international research in gene and cell therapy. His dual background, holding an M.D. from Tongji Medical College and a Ph.D. from the Australian National University, provides clinical and research expertise to evaluate the next generation of potential cancer breakthroughs.
“This journal specifically focuses on oncology and molecular therapies, covering everything from immunotherapy to viral therapy,” said Zhang. “I am glad to have the opportunity to serve the community and represent our university on this international stage.”
Dr. Zhang’s leadership reflects NSM’s growing influence in cancer research and its commitment to high-impact scientific discovery.